AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:29 2025-07-09 am EDT			5-day change	1st Jan Change
10,362.00 ^GBX	+0.21%		-0.38%	-1.01%

Jul. 09	Major deals involving U.S. drugmakers and biotechs over the past decade	RE
Jul. 09	Berenberg Lifts AstraZeneca Price Target, Earnings Forecasts on Drug Pipeline Strength	MT

ASTRAZENECA : Buy rating from JP Morgan

Published on 06/02/2025 at 14:24

James Gordon from JP Morgan retains his positive opinion on the stock with a Buy rating. The target price remains set at GBX 10720.

Latest news about AstraZeneca PLC

Major deals involving U.S. drugmakers and biotechs over the past decade	Jul. 09	RE
Berenberg Lifts AstraZeneca Price Target, Earnings Forecasts on Drug Pipeline Strength	Jul. 09	MT
Berenberg Lifts Price Target on Astrazeneca to $97 From $93, Keeps Buy Rating	Jul. 09	MT
ASTRAZENECA : Deutsche Bank gives a Neutral rating	Jul. 09	ZD
ASTRAZENECA : Berenberg raises target price	Jul. 09	CF
Jefferies says buy BAT and Imperial Brands	Jul. 09	AN
Europe rises despite new US tariff mayhem	Jul. 09	AN
ASTRAZENECA : Berenberg keeps its Buy rating	Jul. 09	ZD
Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn	Jul. 08	RE
Swedish Stocks in North America - Ericsson Drops 1.0 Percent	Jul. 08	FW
The importance of being constantly changing…	Jul. 07
European Union Approves Imfinzi®? for the Treatment of Adult Patients with Resistant Muscle-Invasive Bladder Cancer	Jul. 07	CI
AstraZeneca bladder cancer treatment secures EU approval	Jul. 04	AN
UK Stocks Flat; AstraZeneca Gains on EU Win	Jul. 04	MT
Stocks fade as tariff deadline looms large	Jul. 04	AN
Global markets live: Boeing, Tesla, Nvidia, Stellantis, Commerzbank…	Jul. 04
IAR Soars on Takeover Bid, OMXS30 Index Drops 0.9 Percent	Jul. 04	FW
Health Rounds: Widely used pain drug can be made from plastic waste	Jul. 04	RE
Europe down ahead of US tariff decision deadline	Jul. 04	AN
AstraZeneca's Imfinzi Becomes First Perioperative Bladder Cancer Treatment in EU	Jul. 04	MT
ASTRAZENECA : Gets a Buy rating from UBS	Jul. 04	ZD
AstraZeneca: Imfinzi approved in EU	Jul. 04	CF
Stockholm Bullets – IAR Surges After Takeover Bid With Substantial Premium	Jul. 04	FW
AstraZeneca bladder cancer treatment Imfinzi secures EU approval	Jul. 04	AN
AstraZeneca wins EU nod for bladder cancer therapy	Jul. 04	AN

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

Jul. 29 - Q2 2025 Earnings Release

More about the company